SCHEMBL14608982

SCHEMBL14608982

C(=N/Cc1ccccc1)\c1cccc2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ THRB P10828 2/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ HSD17B10 Q99714 2/20 0.58
▸ GAA P10253 2/20 0.58
▸ ALDH1A1 P00352 2/20 0.58
▸ POLB P06746 1/20 0.58
▸ HPGD P15428 1/20 0.58
▸ ALOX15 P16050 1/20 0.58
▸ NPSR1 Q6W5P4 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.58
▸ GRIN2D O15399 2/20 0.47
▸ GRIN3B O60391 2/20 0.47
▸ GRIN1 Q05586 2/20 0.47
▸ GRIN2A Q12879 2/20 0.47
▸ GRIN2B Q13224 2/20 0.47
▸ GRIN2C Q14957 2/20 0.47
▸ GRIN3A Q8TCU5 2/20 0.47
▸ NPC1 O15118 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30482181 1.00 MAPT (0.58) MAPTKDM4ETHRBTDP1HSD17B10
SCHEMBL8546761 1.00 MAPT (0.58) MAPTKDM4ETHRBTDP1HSD17B10
SCHEMBL25379010 0.92 MAPT (0.51) MAPTKDM4ETHRBTDP1HSD17B10
SCHEMBL5588598 0.81 CA12 (0.53) MAPTKDM4EHSD17B10ALDH1A1POLB
SCHEMBL5693725 0.81 CA12 (0.53) MAPTKDM4EHSD17B10ALDH1A1POLB
SCHEMBL5590740 0.78 CA12 (0.56) MAPTKDM4ETDP1HSD17B10GAA
SCHEMBL5693805 0.78 CA12 (0.56) MAPTKDM4ETDP1HSD17B10GAA
SCHEMBL474244 0.75 GRIN2D (0.51) MAPTKDM4EHSD17B10GAAALDH1A1
SCHEMBL474245 0.75 GRIN2D (0.51) MAPTKDM4EHSD17B10GAAALDH1A1
SCHEMBL27778326 0.75 GRIN2D (0.51) MAPTKDM4EHSD17B10GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136594-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-01 — — US disclosed
EP-4469438-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146987-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
EP-1750487-A1 ORGANIC ELECTROLUMINESCENT DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2007-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136594-A1 COMPOUNDS AND METHODS OF USE CNKSR1, UGT1A1, REV1 MAPT 3881/4885KDM4E 1639/4885THRB 2125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback